Immix Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Immix Biopharma (IMMX).

Price Target Range — 9 Quarters

Analyst Consensus — 7 Analysts

1S.Buy

6Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$24Upside to Avg. PT+231.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	Needham	Gil Blum	PT Raise	Buy	$21→$30
Sep 15, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$15→$26
Aug 11, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$20→$19
Aug 10, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$20→$25
Jul 22, 2026	Needham	Gil Blum	Initiate	Buy	$21
Jun 18, 2026	B of A Securities	Tazeen Ahmad	Initiate	Buy	$27
Jun 17, 2026	LifeSci Capital	—	Initiate	Outperform	$19
May 22, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$15→$20
Mar 30, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$15
Mar 30, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$14→$15
Mar 27, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$23
Mar 27, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$12→$15
Mar 25, 2026	Morgan Stanley	Judah Frommer	Initiate	Overweight	$20
Mar 9, 2026	Citizens	Reni Benjamin	Initiate	Market Outperform	$23
Feb 9, 2026	Mizuho	Graig Suvannavejh	Initiate	Outperform	$14
Dec 9, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$8→$12
Sep 12, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$7→$8
Jun 4, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$7
Feb 10, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$7
Jan 6, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$7

Analyst Ratings News

PRO
Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30

Needham analyst Gil Blum maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $21 to $30.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and raises the price target from $15 to $26.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

Morgan Stanley analyst Judah Frommer maintains Immix Biopharma (NASDAQ:IMMX) with a Overweight and lowers the price target from $20 to $19.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25

HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $20 to $25.

Benzinga Newsdesk

PRO
Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21

Needham analyst Gil Blum initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $21.

Benzinga Newsdesk

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.

Vandana Singh

Immix Biopharma Inc

Immix Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30

PRO
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

PRO
Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

PRO
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25

PRO
Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

People Also Watch

People Also Watch

Immix Biopharma Inc

Immix Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRONeedham Maintains Buy on Immix Biopharma, Raises Price Target to $30

PROMizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

PROMorgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

PROHC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25

PRONeedham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

People Also Watch

People Also Watch

PRO
Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30

PRO
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

PRO
Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

PRO
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25

PRO
Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21